Search details
1.
A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs.
Blood
; 138(21): 2031-2041, 2021 11 25.
Article
in English
| MEDLINE | ID: mdl-34407542
2.
Asciminib vs bosutinib in chronic-phase chronic myeloid leukemia previously treated with at least two tyrosine kinase inhibitors: longer-term follow-up of ASCEMBL.
Leukemia
; 37(3): 617-626, 2023 03.
Article
in English
| MEDLINE | ID: mdl-36717654
3.
Durable treatment-free remission in patients with chronic myeloid leukemia in chronic phase following frontline nilotinib: 96-week update of the ENESTfreedom study.
J Cancer Res Clin Oncol
; 144(5): 945-954, 2018 May.
Article
in English
| MEDLINE | ID: mdl-29468438
4.
Effects of famotidine or an antacid preparation on the pharmacokinetics of nilotinib in healthy volunteers.
Cancer Chemother Pharmacol
; 71(1): 219-26, 2013 Jan.
Article
in English
| MEDLINE | ID: mdl-23070146
Results
1 -
4
de 4
1
Next >
>>